amsacrine has been researched along with Phlebitis in 5 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Phlebitis: Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 7.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 7.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| "The ultimate aim of this study was to develop asulacrine (ASL)-loaded long-circulating liposomes to prevent phlebitis during intravenous (i." | 3.81 | Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. ( Amirapu, S; Baguley, BC; Liu, J; See, E; Shaw, JP; Wang, G; Wu, Z; Zhang, W, 2015) |
| "Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 3.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 3.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Wang, G | 1 |
| See, E | 1 |
| Shaw, JP | 1 |
| Baguley, BC | 1 |
| Liu, J | 1 |
| Amirapu, S | 1 |
| Wu, Z | 1 |
| Micetich, KC | 1 |
| Zwelling, LA | 1 |
| Gormley, P | 1 |
| Young, RC | 1 |
| Issell, BF | 1 |
| Ma, XJ | 1 |
| Xiang, YM | 1 |
| Hong, J | 1 |
| Coates, AS | 1 |
| Bishop, J | 1 |
| Mann, GJ | 1 |
| Raghavan, D | 1 |
5 other studies available for amsacrine and Phlebitis
| Article | Year |
|---|---|
Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation.
Topics: Amsacrine; Animals; Antineoplastic Agents; Chemical Precipitation; Infusion Pumps; Injections; Lipos | 2015 |
Phase I-II study of m-AMSA administered as a continuous infusion.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow; Drug Evaluation; Female; Humans; Kine | 1982 |
Amsacrine (AMSA).
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dogs; Dose-Response Rel | 1980 |
[Venous protection of acute leukemia treatment with amsacrine].
Topics: Acute Disease; Amsacrine; Antineoplastic Agents; Fluid Therapy; Humans; Leukemia; Phlebitis | 1996 |
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Topics: Aminoacridines; Amsacrine; Anthracenes; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Fema | 1986 |